Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company discusses ongoing expansions and capex for augmenting capabilities but does not mention raising funds specifically via debt or equity. Focus is on operational improvements, capacity utilization, and commercial ramp-up of projects like Baker Hughes contract. Insurance claims related to the fire accident are expected to result in inflows in Q3 FY'25, which may support cash flows. Management aims to improve working capital cycles and operating cash flow, suggesting emp

Any current/future capex/capital investment/strategic investment?

Ongoing capex across multiple sites to augment capabilities, focusing on chemical reaction capabilities from R&D to commercial scale (Page 5-6). Expansion of R&D infrastructure with a 2x increase planned at the existing site by 2025 (Page 11). Construction of Site 5 (Panoli), a greenfield expansion with 16 production blocks planned; Phase 1 expected to complete by Q3 FY 2025-26 (Pages 4, 10-11). Commissioning of Site 3+ and 3++ expected in early Q1 FY 2025-26 (Page 4). Enhancements and revamping of fire-affected Site 2 targeting 100% operations by mid-November 2024 (Pages 4-5). 15 MW solar pow

Future growth expectations in sales/revenue/volumes?

The demand for products remains strong with volume growth seen across all three business models: large-scale manufacturing, contract/exclusive manufacturing, and CRAMS. The company added 12 new clients in the recent quarter, indicating expanding customer base. Contract/exclusive manufacturing revenues are expected to rise significantly from Q3 and Q4 FY25 with commercial orders from Baker Hughes starting then. Pricing pressures from Chinese competition have kept prices low, but price correction is anticipated from Q4 FY25 or Q1 calendar year 2025, which should improve margins. The CRAM

Future growth expectations in earnings/operating earnings/profits/EPS?

Target to inch EBITDA margins back to traditional levels of around 28%-30% by second half of the year (Rohan Desai, Page 14). Expect improvement in pricing starting Q4 FY25 / Q1 calendar year 2025, which should enhance margins (Rohan Desai, Pages 9 and 7). PAT margin improved from 16%-17% in Q1 to 17%-18% in Q2 FY25, indicating a positive earnings trend (Page 4). CRAMS business model seen as a significant growth engine with optimistic outlook and continuous addition of customers (Aman Desai, Page 11). Revenue growth is expected with full operations expected at the fire-affected site by mid-Nov

Current/ Expected Orderbook/ Pending Orders?

Aether Industries has ongoing contract/exclusive manufacturing orders, including a contract with SEQENS Group for launch and market development quantities (100 metric tons), with expectations of significantly higher commercialization volumes in the future. The Baker Hughes contract faced delays, impacting revenue guidance for the current fiscal year, but the guidance for next year remains intact (~INR 350 crores for next year). Multiple advanced projects in renewables, sustainability, pharma, agrochemicals, and oil and gas sectors are in advanced stages at various sites, including Site 3++ and

IN US

Sale is live|00:00:00left today

Aether Industries LtdQ3 FY24Chemicals & Petrochemicals

Aether Industries Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,325P/E: 65.2Market Cap: ₹14.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The demand for products remains strong with volume growth seen across all three business models: large-scale manufacturing, contract/exclusive manufacturing, and CRAMS.
→The company added 12 new clients in the recent quarter, indicating expanding customer base.
→Contract/exclusive manufacturing revenues are expected to rise significantly from Q3 and Q4 FY25 with commercial orders from Baker Hughes starting then.
→Pricing pressures from Chinese competition have kept prices low, but price correction is anticipated from Q4 FY25 or Q1 calendar year 2025, which should improve margins.
→The CRAMS business model is seen as the growth engine, with expanded R&D, pilot plant capabilities, and ongoing addition of innovative customers.
→Panoli Site 5 expansion with 16 production blocks will increase capacity with visibility on 40–45% of production already.
→Overall, the company targets a return to EBITDA margins of around 28–30% and expects volume and revenue growth across pharmaceutical, agrochemical, renewables, and oil & gas sectors.

Margin guidance

Category 3

→Target to inch EBITDA margins back to traditional levels of around 28%-30% by second half of the year (Rohan Desai, Page 14).
→Expect improvement in pricing starting Q4 FY25 / Q1 calendar year 2025, which should enhance margins (Rohan Desai, Pages 9 and 7).
→PAT margin improved from 16%-17% in Q1 to 17%-18% in Q2 FY25, indicating a positive earnings trend (Page 4).
→CRAMS business model seen as a significant growth engine with optimistic outlook and continuous addition of customers (Aman Desai, Page 11).
→Revenue growth is expected with full operations expected at the fire-affected site by mid-November 2024 and new projects commissioning in FY26 (Pages 4 and 5).
→New contract manufacturing projects, including Baker Hughes, expected to contribute significantly from Q3 FY25 onwards (Pages 12 and 10).
→Working capital improvements should positively impact cash flow and earnings (Page 10).

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company discusses ongoing expansions and capex for augmenting capabilities but does not mention raising funds specifically via debt or equity.
→Focus is on operational improvements, capacity utilization, and commercial ramp-up of projects like Baker Hughes contract.
→Insurance claims related to the fire accident are expected to result in inflows in Q3 FY'25, which may support cash flows.
→Management aims to improve working capital cycles and operating cash flow, suggesting emphasis on internal accruals rather than external fundraising at this time.

Order book

Yes

→Aether Industries has ongoing contract/exclusive manufacturing orders, including a contract with SEQENS Group for launch and market development quantities (100 metric tons), with expectations of significantly higher commercialization volumes in the future.
→The Baker Hughes contract faced delays, impacting revenue guidance for the current fiscal year, but the guidance for next year remains intact (~INR 350 crores for next year).
→Multiple advanced projects in renewables, sustainability, pharma, agrochemicals, and oil and gas sectors are in advanced stages at various sites, including Site 3++ and Panoli (Site 5).
→The company has visibility for 6-7 production blocks out of 16 planned in Panoli, covering both in-house molecules and contract manufacturing.
→New customer additions include 12 clients this quarter, mainly in pharma, agro, coatings, and CRAMS segments, indicating ongoing orderbook expansion.

Capex plans

Yes

→Ongoing capex across multiple sites to augment capabilities, focusing on chemical reaction capabilities from R&D to commercial scale (Page 5-6).
→Expansion of R&D infrastructure with a 2x increase planned at the existing site by 2025 (Page 11).
→Construction of Site 5 (Panoli), a greenfield expansion with 16 production blocks planned; Phase 1 expected to complete by Q3 FY 2025-26 (Pages 4, 10-11).
→Commissioning of Site 3+ and 3++ expected in early Q1 FY 2025-26 (Page 4).
→Enhancements and revamping of fire-affected Site 2 targeting 100% operations by mid-November 2024 (Pages 4-5).
→15 MW solar power plant installation underway, with 10 MW commissioned and remaining 5 MW expected by October 2024, supporting sustainability and operational cost savings (Page 4).
→Capex supporting growth in CRAMS business and contract manufacturing, including partnerships like Baker Hughes and SEQENS Group (Pages 5-6, 10-12).

How does Aether Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aether Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aether Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio